The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Multiple myeloma: highlights at ASH 2020
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses some of the highlights in multiple myeloma presented at ASH 2020. The impact of measurable residual disease (MRD) on patient outcomes is discussed, as well as the importance of using MRD as a way of evaluating treatments in the future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ, Actinuum
